Stock Comparison

ABBV vs INCY

AbbVie Inc vs Incyte Corp

The Verdict

INCY takes this one.

ABBV

AbbVie Inc

0.1

out of 10

Distressed

Winner

INCY

Incyte Corp

0.6

out of 10

Distressed

Head-to-Head

$381.1B

Market Cap

$20.8B

104.8

P/E Ratio

14.5

5.8%

Profit Margin

26.7%

95.6%

Return on Equity

29.2%

20.2

Debt-to-Equity

0.0

Moderate

Overall Risk

Moderate

0.1

DVR Score

0.6

The Deep Dive

ABBV0.1/10

AbbVie (ABBV) remains a well-established mega-cap pharmaceutical company, demonstrating stable, incremental growth driven by its robust immunology portfolio, notably Skyrizi and Rinvoq. Q1 2026 results showed modest revenue and adjusted EPS growth, with slightly raised full-year guidance. While financially healthy and a strong dividend payer, its immense market capitalization ($381.10B) and the ma...

Full ABBV Analysis

INCY0.6/10

Incyte (INCY) is a well-established large-cap biopharmaceutical company ($20.45B market cap) showing solid Q1 2026 performance with an 85.4% YoY EPS beat and positive pipeline updates for zilurgisertib and Opzelura. These factors suggest continued steady growth and operational strength. However, consistent with previous analysis, its current size and operational maturity in the biopharmaceutical s...

Full INCY Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.